DXVX

180400KOSDAQ기타 과학기술 서비스업

45.5 / 100

Reference Date: 2026-07-24

Financial Score9.0 / 40

News Sentiment20.4 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: Revenue is on a declining trend, Operating Profit is on a declining trend. Rose 5.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DXVX is a biopharmaceutical company specializing in medical diagnostics, healthcare, and drug development, expanding globally through the 2022 acquisition of Hanbio Pharm and the 2023 establishment of a Chinese subsidiary. In medical diagnostics, it leverages NGS and AI-based platforms with GMP-certified facilities, while its drug development focuses on oncology therapies through partnerships with Stanford University and the acquisition of Evexis Gen. The company plans to mitigate financial risks by licensing technologies to major pharmaceutical firms.

Number of Employees

62people

Average Salary

107.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 13.254.0Point

PBR

2.36Industry Average 1.351.0Point

1.7x industry avg (risky)

ROE

-52.77Industry Average -0.673.5Point

78.8x industry avg (excellent)

Debt Ratio

39.00Industry Average 25.420.5Point

1.5x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼45.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -123.0% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 10Neutral 1Negative 0Average Sentiment Score 81.8

Positive
디엑스앤브이엑스, 아르헨티나 바이오기업과 KRNA 기술 MTA 체결
DXVX secures its first material transfer agreement (MTA) license in South America with an Argentine biotech firm, signaling strong international expansion potential.
Positive
DXVX, 아르헨티나 제약사와 'KRNA' 물질이전계약 체결
DXVX secures material transfer agreement with Argentine pharmaceutical firm for KRNA technology, indicating promising progress towards commercialization.
Positive
"남미 영역 확장"…DXVX·아르헨 제약사, MTA 체결
DXVX secures MTA with Argentine biotech firm, indicating strategic expansion and potential market access boost.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 2,300Won52-week high 5,11052-week low 1,653

1-month return4.0Point

1m +5.02% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-16
Neutral주식등의대량보유상황보고서(일반)2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-10
Neutral주식등의대량보유상황보고서(일반)2026-06-26
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-26